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Abstract Purpose: Acute gastro-
intestinal (GI) dysfunction and failure
have been increasingly recognized in
critically ill patients. The variety of
deﬁnitions proposed in the past has
led to confusion and difﬁculty in
comparing one study to another. An
international working group con-
vened to standardize the deﬁnitions
for acute GI failure and GI symptoms
and to review the therapeutic options.
Methods: The Working Group on
Abdominal Problems (WGAP) of the
European Society of Intensive Care
Medicine (ESICM) developed the
deﬁnitions for GI dysfunction in
intensive care patients on the basis of
the available evidence and current
understanding of the pathophysiol-
ogy. Results: Deﬁnitions for acute
gastrointestinal injury (AGI) with its
four grades of severity, as well as for
feeding intolerance syndrome and GI
symptoms (e.g. vomiting, diarrhoea,
paralysis, high gastric residual vol-
umes) are proposed. AGI is a
malfunctioning of the GI tract in
intensive care patients due to their
acute illness. AGI grade
I = increased risk of developing GI
dysfunction or failure (a self-limiting
condition); AGI grade II = GI dys-
function (a condition that requires
interventions); AGI grade III = GI
failure (GI function cannot be
restored with interventions); AGI
grade IV = dramatically manifesting
GI failure (a condition that is imme-
diately life-threatening). Current
evidence and expert opinions regard-
ing treatment of acute GI dysfunction
are provided. Conclusions: State-of-
the-art deﬁnitions for GI dysfunction
with gradation as well as management
recommendations are proposed on the
basis of current medical evidence and
expert opinion. The WGAP recom-
mends using these deﬁnitions for
clinical and research purposes.
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Failure  Symptoms  Feeding
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More than 10 years ago a round-table conference on gut
dysfunction in critical illness concluded that intestinal
function is an important determinant in the outcome of
patients admitted to the intensive care unit (ICU), but that
there is no objective and clinically relevant deﬁnition of
gastrointestinal (GI) dysfunction in critical illness. In
addition, it was stated that the deﬁnition developed in the
future should grade the severity of dysfunction [1].
The problems in deﬁning GI dysfunction start with
deﬁning GI function. Next to the digestive tract, the GI
tract also carries out endocrine, immune and barrier
functions. The clinical assessment of the impairment of
these functions today is more intuitive than objective.
Therefore, endocrine, immune and barrier dysfunctions
will not be addressed in detail in the present paper.
Several studies have conﬁrmed that GI symptoms are
frequent in the ICU with up to 62% of patients exhibiting at
least one GI symptom for at least 1 day [2–4]. There is also
increasing evidence that development of GI problems is
related to worse outcome in critically ill patients [2, 5–7].
Different deﬁnitions for separate GI symptoms have
been used. The lack of markers for the measurement of GI
function has suppressed studies in this ﬁeld as well as the
assessment of GI dysfunction as an organ failure.
Although plasma citrulline and intestinal fatty acid
binding protein have been proposed as possible markers
for small bowel function [8], their clinical use in diag-
nosis and management of GI dysfunction is still unclear.
At least partly due to the lack of a formal deﬁnition
and classiﬁcation, treatment strategies for GI problems
have been difﬁcult to develop and are currently based on
experience, rather than evidence.
There is increasing evidence that early protocolized
and goal-oriented care can improve organ function and
the patients’ outcome during critical illness [9–12].
Improving the deﬁnition of GI dysfunction as a part of the
multiple organ dysfunction syndrome (MODS) and its
derived sequential organ failure assessment score (SOFA)
[13] will establish the base for setting up the bundle of
preventive and therapeutic measures and support the
development of novel treatment strategies.
For these reasons, the Working Group on Abdominal
Problems (WGAP) as part of the Perioperative Intensive
Care (POIC) section of the European Society of Intensive
Care Medicine (ESICM) proposes a set of deﬁnitions and
grading system of GI dysfunction in critical illness that
are applicable both for clinical and research purposes.
Methods
Several key elements were used as a starting point for
deﬁning acute GI organ failure. An organ failure was
considered as a dichotomous event that is either present or
absent, whereas organ dysfunction is a continuum of
physiologic derangement [14]. The expression ‘‘GI dys-
function’’ is used to describe the large variety of GI
symptoms (diarrhoea, vomiting) and diagnoses (gastro-
enteritis) outside of the ICU setting; therefore, the
expression ‘‘acute GI injury’’ was introduced.
Current deﬁnitions and management recommendations
(according to Table 1;[ 15]) were developed on the basis
of the available evidence and current understanding of the
pathophysiology. Deﬁnitions serve as expert opinion, with
their reasoning given in each ‘‘rationale’’ subsection.
The working method is described in detail in the
electronic supplementary ﬁle.
Results
The WGAP suggests using the following terminology and
deﬁnitions:
1. Gastrointestinal function
The human GI tract has many functions including
facilitating digestion to absorb nutrients and water,
barrier control to modulate absorption of intraluminal
microbes (and their products), endocrine and immune
functions. Perfusion, secretion, motility and a coordi-
nated gut–microbiome interaction are prerequisites for
an adequate function [16].
It needs to be underlined that because we currently
lack the tool or marker to measure GI function we
cannot reliably decide about normal GI function in the
acute setting.
2. Acute gastrointestinal injury (AGI) and its different
grades
Acute GI injury (AGI) is malfunctioning of the GI
tract in critically ill patients due to their acute illness.
According to severity the following grades of AGI can
be distinguished:
Table 1 Grading of the quality of evidence and strength of
recommendations
Quality of evidence Rationale
A High RCT or meta-analyses
B Moderate Downgraded RCTs or upgraded
observational studies
C Low Well-done observational studies
D Very low Case series or expert opinion
Strength of recommendation
Grade 1 Strong We recommend
Grade 2 Weak We suggest
RCT randomized controlled trial
3852.1 AGI grade I (risk of developing GI dysfunction or
failure)—the function of the GI tract is partially
impaired, expressed as GI symptoms related to a
known cause and perceived as transient.
Rationale Condition is clinically seen as occur-
rence of GI symptoms after an insult, which
expectedly has temporary and self-limiting
nature.
Examples Postoperative nausea and/or vomiting
during the ﬁrst days after abdominal surgery,
postoperative absence of bowel sounds, dimin-
ished bowel motility in the early phase of
shock.
Management The general condition is usually
improving and speciﬁc interventions for GI
symptoms are not needed, except the replace-
ment of ﬂuid requirements by intravenous
infusions. Early enteral feeding, started within
24–48 h after the injury, is recommended [17,
18] (grade 1B). The use of drugs impairing GI
motility (e.g. catecholamines, opioids) has to be
limited whenever possible [19–22] (grade 1C).
2.2 AGI grade II (gastrointestinal dysfunction)—the GI
tract is not able to perform digestion and
absorption adequately to satisfy the nutrient
and ﬂuid requirements of the body. There are
no changes in general condition of the patient
related to GI problems.
Rationale The condition is characterized by
acute occurrence of GI symptoms requiring
therapeutic interventions for achievement of
nutrient and ﬂuid requirements. This condition
occurs without previous GI interventions or is
more severe than might be expected in relation to
the course of preceding abdominal procedures.
Examples Gastroparesis with high gastric resid-
uals or reﬂux, paralysis of the lower GI tract,
diarrhoea, intra-abdominal hypertension (IAH)
grade I (intra-abdominal pressure (IAP)
12–15 mmHg), visible blood in gastric content
or stool. Feeding intolerance is present if at least
20 kcal/kg BW/day via enteral route cannot be
reached within 72 h of feeding attempt.
Management Measures to treat the condition and
to prevent the progression to GI failure need to be
undertaken (e.g. treatment of intra-abdominal
hypertension [23], grade 1D; or measures to
restore the motility function of GI tract, such as
prokinetic therapy [24–26], grade 1C). Enteral
feeding should be started or continued; in cases of
high gastric residuals/reﬂux or feeding intoler-
ance regular challenges with small amounts of
enteral nutrition (EN) should be regularly con-
sidered (grade 2D). In patients with gastroparesis,
initiation of postpyloric feeding should be
considered in this state, when prokinetic therapy
is not effective (grade 2D).
2.3 AGI grade III (gastrointestinal failure)—loss of GI
function, where restoration of GI function is not
achieved despite interventions and the general
condition is not improving.
Rationale Clinically seen as sustained intoler-
ance to enteral feeding without improvement
after treatment (e.g. erythromycin, postpyloric
tube placement), leading to persistence or wors-
ening of MODS.
Examples Despite treatment, feeding intolerance
is persisting—high gastric residuals, persisting
GI paralysis, occurrence or worsening of bowel
dilatation, progression of IAH to grade II (IAP
15–20 mmHg), low abdominal perfusion pres-
sure (APP) (below 60 mmHg). Feeding
intolerance is present and possibly associated
with persistence or worsening of MODS.
Management Measures to prevent worsening of
GI failure are warranted (e.g. monitoring and
targeted treatment of IAH [23], grade 1D).
Presence of undiagnosed abdominal problem
(cholecystitis, peritonitis, bowel ischaemia)
should be excluded. The medications promoting
GI paralysis have to be discontinued as far as
possible [19–22] (grade 1C). Early parenteral
feeding (within the ﬁrst 7 days of ICU stay)
supplementary to insufﬁcient enteral nutrition is
associated with higher incidence of hospital
infections and should be avoided [27] (grade
2B). Challenges with small amounts of EN
should be regularly considered (grade 2D).
2.4 AGI grade IV (gastrointestinal failure with severe
impact on distant organ function)—AGI has pro-
gressed to become directly and immediately life-
threatening, with worsening of MODS and shock.
Rationale Situation when AGI has led to an acute
criticaldeteriorationofthegeneralconditionofthe
patient with distant organ dysfunction(s).
Examples Bowel ischaemia with necrosis, GI
bleeding leading to haemorrhagic shock, Ogilvie’s
syndrome, abdominal compartment syndrome
(ACS) requiring decompression.
Management Condition requires laparotomy or
other emergency interventions (e.g., colonoscopy
for colonic decompression) for life-saving indica-
tions [28–30] (grade 1D). There is no proven
conservative approach to resolve this situation.
As differentiation of the acute GI problem from
previouslyexistingchronicconditionmightbevery
difﬁcult,wesuggestusingthesamedeﬁnitionsalso
in cases where the condition (e.g. GI bleeding,
diarrhoea,etc.)mightbeduetoachronicGIdisease
386(e.g. Crohn’s disease). In patients on chronic
parenteral feeding, GI failure (equal to AGI III)
should be considered chronically present, and no
new acute interventions to restore function are
indicated.However, monitoring ofIAH and exclu-
sion of the new acute abdominal problems should
be performed similarly as in AGI grade III
management.
2.5 Primary and secondary AGI
2.5.1 Primary AGI is associated with primary disease or
direct injury to organs of the GI system
(ﬁrst hit).
Rationale Condition may usually be
observed early (during the ﬁrst day) after
the insult to the GI system.
Examples Peritonitis, pancreatic or
hepatic pathology, abdominal surgery,
abdominal trauma, etc.
2.5.2 Secondary AGI develops as the consequence of a
host response in critical illness without
primary pathology in the GI system
(second hit).
Rationale Condition develops without
direct insult to the GI tract.
Examples GI malfunction in a patient
with pneumonia, cardiac pathology, non-
abdominal surgery or trauma, postresus-
citation state.
3. Feeding intolerance syndrome (FI)
FI is a general term indicating intolerance of enteral
feeding for whatever clinical reason (vomiting, high
gastric residuals, diarrhoea, GI bleeding, presence of
entero-cutaneous ﬁstulas, etc.).
Rationale Diagnosis is based on complex clinical
evaluation. There is no single clear-cut symptom or
value that deﬁnes FI [31]. Several symptoms are
commonly present.
FI should be considered present if at least 20 kcal/
kg BW/day via enteral route cannot be reached within
72 h of feeding attempt or if enteral feeding has to be
stopped for whatever clinical reason. FI should not be
considered as present if enteral feeding is electively not
prescribed or is withheld/interrupted due to procedures.
FI in special conditions: in a patient with postpyloric
feeding, FI is deﬁned similarly to gastric feeding. If a
patient is not fed enterally due to the presence of entero-
atmospheric ﬁstulas, FI should be considered present. If
the patient undergoes a surgical intervention for ACS or
for changing of surgical dressings of an open abdomen,
FI should be considered present immediately after
surgery unless enteral feeding can be administered.
Management FI requires efforts to maintain/restore GI
function: limiting the use of drugs impairing motility,
application of prokinetics and/or laxatives [32–34]
(grade 1C), and controlling IAP. Challenges with
small amounts of EN should be regularly considered.
In patients not tolerating enteral feeding, supplemental
parenteral nutrition should be considered [35, 36]
(grade 2D). Recent data suggest that delay for 1 week
with parenteral nutrition enhances recovery when
compared to early intravenous feeding [27] (grade
2B).
4. Intra-abdominal hypertension (IAH)
4.1 IAH is present if IAP is found to be 12 mmHg or
higher, conﬁrmed by at least two measurements,
1–6 h apart [37].
Rationale Normal IAP is around 5–7 mmHg [38].
There are inherent variations and ﬂuctuations in
the IAP. IAH should also be considered present if
the mean of the IAP measurements of the day is
12 mmHg or higher provided that at least four
measurements were performed [39].
Management Monitoring of ﬂuid resuscitation is
necessary to avoid over-resuscitation [23] (grade
1C). Continuous thoracic epidural analgesia may
decrease IAP in postoperative patients with
primary IAH [40] (grade 2B). Nasogastric/colonic
decompression is suggested for evacuation of
intraluminal contents [23] (grade 2D). In patients
with intraperitoneal ﬂuids, percutaneous catheter
decompression is recommended [23] (grade 1C).
Elevation of head of bed above 20 should be
considered as an additional risk for development
of IAH [23] (grade 2C). Neuromuscular blockade
decreases the IAP [41], but due to many undesir-
able effects it should be considered only in
selected patients (grade 2C).
4.2 Abdominal compartment syndrome (ACS) is
deﬁned as a sustained (minimally two standard-
ized measurements, performed 1–6 h apart)
increase in IAP above 20 mmHg with new onset
organ failure [37].
Management Although decompression remains
the only deﬁnite management for ACS, the exact
indications and timing of this procedure still
remain controversial [42]. Currently it is recom-
mended (1) to perform surgical decompression as
a life-saving intervention in patients with ACS
that is refractory to other treatment options [28,
43] (grade 1D), and (2) to consider pre-emptive
decompression at the time of laparotomy in
patients who demonstrate multiple risk factors
for IAH/ACS [23] (grade 1D). In most severe
cases of ruptured abdominal aortic aneurysm or
abdominal trauma the initial use of mesh closure
avoids development of ACS [44, 45] (grade 1C).
3875. Gastrointestinal symptoms
5.1 Vomiting (emesis) is the occurrence of any visible
regurgitation of gastric content irrespective of
the amount.
Rationale Vomiting is commonly deﬁned as the
oral expulsion of GI contents resulting from
contractions of gut and thoracoabdominal wall
musculature [46]. Vomiting is contrasted with
regurgitation, which is the effortless passage of
gastric contents into the mouth [46]. In ICU
patients the forcefulness of the act is often not
detectable; therefore, regurgitation and vomiting
should be assessed together.
Management Several guidelines for prevention
and management of postoperative nausea and
vomiting are available [47–51]. However, no
studies have addressed management of vomiting
in mechanically ventilated ICU patients; there-
fore, no speciﬁc recommendation can be given.
5.2 Gastric residual volume could be considered high if
a single volume exceeds 200 ml [52–54].
Rationale There is no sufﬁcient scientiﬁc evi-
dence or physiological ground to deﬁne precise
values for high gastric residuals [53, 55]. Mea-
surement of gastric residuals is neither
standardized nor validated [56]. It has been
suggested that gastric residual volume greater
than 200 ml should prompt careful bedside
evaluation, but automatic cessation of enteral
nutrition solely on the basis on residual volumes
of 200–500 ml should be avoided [53, 56, 57].
Despite the lack of scientiﬁc evidence, the
members of the WGAP arbitrarily use total
volumes of gastric residuals above 1,000 ml/
24 h as a sign of abnormal gastric emptying,
which requires speciﬁc attention.
Management Intravenous administration of met-
oclopramide and/or erythromycin is
recommended for management of high gastric
residuals, whereas cisapride is no longer
approved [58] (grade 1B). Routine use of
motility agents is not recommended [58] (grade
1A). Acupuncture stimulation may facilitate
gastric empting in neurosurgical ICU patients
[59] (grade 2B). Use of opioids and deep
sedation should be avoided/reduced if possible.
Cessation of gastric feeding is suggested if
residual volumes exceed 500 ml per single
measurement [57]. Here, postpyloric feeding
should be considered [58] (grade 2D). Routine
application of postpyloric feeding is not advo-
cated [58] (grade 2D). Postpyloric feeding may
cause severe small bowel dilatation and perfora-
tion in rare cases.
5.3 Diarrhoea is deﬁned as having three or more loose
or liquid stools per day with a stool weight
greater than 200–250 g/day (or greater then
250 ml/day) [60, 61].
Rationale Normal bowel frequency ranges from
three times a week to three times a day.
Secretory, osmotic, motor and exudative diar-
rhoea may be distinguished [61], but in the ICU
it is often better to distinguish between disease-,
food/feeding- and drug-related diarrhoea [61,
62].
Management Symptomatic therapy—replace-
ment of ﬂuids and electrolytes, haemodynamic
stabilization and organ protection (e.g. correction
of hypovolaemia to prevent impairment of renal
function) forms the basic management [61, 63,
64] (grade 1D). At the same time, trigger
mechanisms need to be discovered and when
possible stopped (e.g. laxatives, sorbitol, lactu-
lose, antibiotics) or treated (e.g. malabsorption,
inﬂammatory bowel disease). Feeding-related
diarrhoea in critically ill patients may require
reduction of infusion rate, repositioning of
feeding tube, or dilution of nutrition formula.
Changing formula by adding soluble ﬁbre pro-
longs transit time [61, 64–66] (grade1C). Only in
cases of severe or recurrent Clostridium difﬁcile-
associated diarrhoea is oral vancomycin superior
to metronidazole [67–69] (grade 2C).
5.4 GI bleeding is any bleeding into the GI tract lumen,
conﬁrmed by macroscopic presence of blood in
vomited ﬂuids, gastric aspirate or stool.
Rationale Asymptomatic, endoscopically evident
mucosal damage occurs in the majority of ICU
patients [2]. Clinically evident GI bleeding
reﬂecting considerable damage to GI mucosa
may be seen in 5–25% of ICU patients [2].
Clinically important bleeding, deﬁned as overt
bleeding in association with haemodynamic
compromise or the need for blood transfusions
[70], occurs in 1.5–4% of mechanically venti-
lated patients [2, 70, 71].
Management In cases of clinically evident GI
bleeding, the haemodynamic status dictates the
approach. In cases of bleeding with haemody-
namic instability endoscopy is the diagnostic tool
of choice [72], but when bleeding is ongoing and
massive, precluding adequate endoscopic assess-
ment, angiography is appropriate (grade 2C).
Early upper GI endoscopy (less than 24 h) is
recommended [72, 73] (grade 1A), except for
patients with acute variceal bleeding in whom a
more expedite procedure (less than 12 h) should
be considered [74] (grade 2C). Epinephrine
injection can be used in combination with
388another method, such as clips, thermocoagula-
tion or sclerosant injection [72] (grade 1A).
Routine second endoscopy is not recommended,
but in cases of rebleeding, a second attempt for
endoscopic therapy is recommended [72] (grade
1A). In cases of a negative upper endoscopy with
evidence of GI bleeding, colonoscopy should be
performed, followed by small bowel exploration
using push enteroscopy if colonoscopy is nega-
tive [75] (grade 2C). In cases of ongoing
bleeding with negative endoscopies, abdominal
surgery with intraoperative endoscopy or inter-
ventional radiology should be considered [76,
77] (grade 2C).
5.5 Paralysis of lower GI tract (paralytic ileus) is the
inability of the bowel to pass stool due to
impaired peristalsis. Clinical signs include
absence of stool for three or more consecutive
days without mechanical obstruction. Bowel
sounds may or may not be present.
Rationale Outside of the ICU, the terms consti-
pation and obstipation include uncomfortable or
infrequent bowel movements, hard stool and
painful defecation. Because these symptoms may
not be expressed in ICU patients, it is suggested
to use the term paralysis of lower GI tract. A cut-
off level of 3 days has been used in most of the
epidemiological ICU studies [78, 79].
Management Inhibitory drugs for GI motility
(e.g. catecholamines, sedatives, opioids) must be
withdrawn if possible and conditions impairing
motility (e.g. hyperglycemia, hypokalaemia)
corrected [19–21] (grade 1C). Because of their
delayed onset of action, laxative drugs must be
started early or given prophylactically [24, 25]
(grade 1D).
Because of unknown long-term efﬁcacy and
safety the routine use of opioid antagonists
cannot be recommended [80, 81] (grade 2B).
Prokinetics like domperidone, metoclopramide
and erythromycin are used to stimulate the upper
GI tract (stomach and small bowel), whereas
neostigmine stimulates small bowel and colonic
motility [25, 30]. Despite the lack of well-
controlled studies and sufﬁcient evidence, we
recommend a standardised approach in using
prokinetics for management of motility disorders
[24, 25] (grade 1D).
5.6 Abnormal bowel sounds
Rationale Normal frequency of bowel sounds
may range between 5 and 35 sounds/min [82];
the clinical signiﬁcance of abnormal bowel
sounds is not clear. No technique of auscultation
has been proven to be superior [83]. The authors
suggest auscultation for at least 1 min in two
quadrants, repeated at least once within a tight
time frame. Palpation of the abdomen before the
auscultation may stimulate peristalsis causing
subsequent bowel sounds that may not have been
there otherwise [82].
5.6.1 Absent peristalsis—no bowel sounds are heard at
cautious auscultation.
Rationale Complete lack of bowel
sounds is abnormal [83]. However, it
should be recognized that presence of
bowel sounds does not conﬁrm normal
motility, and that reoccurrence of bowel
sounds does not correlate with improve-
ment of paralysis.
5.6.2 Hyperperistalsis is present if excessive bowel
sounds are heard on auscultation.
Rationale Hyperperistalsis is a state of
excessive motility of the digestive tract.
It can be present during bowel obstruc-
tion occurring in parts of the bowel as
attempts to overcome obstruction [84].
Management There are no special man-
agement suggestions for absent/abnormal
bowel sounds.
5.7 Bowel dilatation is present if colonic diameter
exceeds 6 cm (greater than 9 cm for caecum) or
small bowel diameter exceeds 3 cm, diagnosed
either on plain abdominal X-ray or CT scan [85,
86].
Rationale Bowel dilatation is a common sign in
obstruction at any level of the GI tract. Bowel
dilatation may also appear without an obstruc-
tion; the terms toxic megacolon following colitis
and acute colonic pseudo-obstruction or Ogil-
vie’s syndrome, are used to describe acute severe
colonic dilatation.
Management Next to the correction of ﬂuid and
electrolyte imbalance, nasogastric decompres-
sion may be helpful [29, 87] (grade 1D),
although routine usage of nasogastric tubes after
elective laparotomy is not recommended [88]
(grade 1A). After exclusion of mechanical
obstruction, intravenous neostigmine could be
considered in patients with a caecal diameter
[10 cm and without improvement within 24 h
[29, 89] (grade 2B). Colonoscopy is recom-
mended for non-surgical decompression in
patients with a caecal diameter [10 cm and no
improvement after 24–48 h of conservative
treatment [29, 87, 90] (grade 1C). Colonoscopic
decompression is effective in up to 80%, but
carries a certain morbidity/mortality risk [30].
Conservative treatment together with colonos-
copy may be continued for 48–72 h unless the
389caecum is [12 cm wide [30, 91] (grade 2C).
In cases of unresponsiveness to conservative
treatment, surgery is indicated due to the threat-
ening risk of perforation [29, 30] (grade 1D).
Usage of a laparoscopic technique with thoracic
epidural anaesthesia where appropriate enhances
bowel function after abdominal surgery [92–94]
(grade 1B), and may therefore prevent bowel
dilatation.
6. Feeding protocols
Decreased food intake and resulting malnutrition
are independent risk factors for in-hospital mortality
[95]. European Society for Parenteral and Enteral
Nutrition (ESPEN) guidelines are available with
recommendations for nutrition in intensive care [58].
Feeding protocols based on these guidelines should be
implemented in every institution. Periods of interrup-
tion of enteral feeding due to various interventions in
the hospital (surgery, diagnostic or therapeutic inter-
ventions, extubation) should be remembered and
minimized [96, 97]. Daily assessment of adequacy of
enteral nutrition is required.
7. A schematic guideline for the management of patients
with AGI is presented in Fig. 1.
Guideline for diagnosis and management of AGI
Enteral feeding >80% of calculated needs Aim 100 % of calculated needs
Check prescribed vs. delivered
Re-evaluate daily
Re-evaluate at least daily
Consider parenteral feeding EF contraindicated?  yes
Shock? 
Re-evaluate at least daily
Start minimal EF (20 ml/h) 
GI symptoms present? 
Moderate, expectedly self-limited
yes
no 
no 
yes
no 
no 
yes
AGI I
Start/increase EF
Use protocol
Re-evaluate daily
Feeding intolerance?
no 
yes
Increase EF
Re-evaluate
AGI IV
Intervention 
AGI II
Start therapy according to the
symptom (e.g. prokinetics) 
Measure IAP
Start minimal enteral feeding
Consider postpyloric feeding
Condition improving?  yes
AGI III
Search for undiagnosed abdominal
pathology
Continue therapy according to the
symptom (e.g. prokinetics) 
Treat IAH
Try (challenge) minimal EF and start PN
Critical decompensation through AGI?
yes
No AGI
Aim 100 % of calculated needs
Check prescribed vs. delivered
Re-evaluate daily
Severe, general condition not
improving
no 
Increase EF
Re-evaluate daily


Fig. 1 Schematic guideline for
the management of patients
with AGI. EF enteral feeding,
EN enteral nutrition, PN
parenteral nutrition
390Discussion
Terminology and deﬁnitions provided in the present paper
weredevelopedwiththeaimofprovidingclinicaldeﬁnitions
which may be used in different ICUs and clinical situations.
Our working methods were similar to those commonly
used for the consensus deﬁnitions and grading of evidence
for the treatment recommendations. The main limitation
of the current document is the lack of objective measures
for GI function/dysfunction. As the evidence in this ﬁeld
is scarce, the deﬁnitions are largely based on expert
opinion. Therefore, in case new established measures to
assess GI function/dysfunction become available, pro-
posed deﬁnitions need to be revised. The complete
description of diagnostic procedures for conditions
underlying AGI is not provided in the current manuscript,
common clinical approach is presumed.
Our grading system is not based on a certain numeric
variable and is not validated. With no doubt further
research is needed to establish the measures of GI function
that could be used in a reproducible manner for grading GI
function. At present, the descriptions of the grades of AGI
are complicated and the same grade of AGI may have
different clinical expressions. It is likely that the score will
in some extent be dependent on the treatment applied. In
fact, other organ dysfunction scores (e.g. SOFA score)
have also been developed ﬁrst, and only validated after-
wards. Moreover, the cardiovascular sub-score of SOFA
[13], known to be the most performing among all the sub-
scores, is deﬁned as a mean arterial pressure and the usage/
dosage of vasoactive/inotropic agents, where the last part
is clearly dependent on the local treatment traditions.
Despite the many well-known limitations which have
been restraining the development in this area for so long,
we need to move forward, and we suggest to start with the
deﬁnitions proposed in this paper.
Summary
The terminology and deﬁnitions provided herein should
allow better clinical communication as well as compar-
ison between future studies. Deﬁning the speciﬁc
variables is the ﬁrst step in a process towards better
knowledge in this area. We propose a deﬁnition of acute
gastrointestinal injury (AGI) with four grades of sever-
ity. AGI grade I stands for a self-limiting condition with
increased risk of developing GI dysfunction or failure;
AGI grade II (GI dysfunction) is a condition requiring
interventions to restore GI function; AGI grade III (GI
failure) is a condition when GI function cannot be
restored with interventions; and AGI grade IV is dra-
matically manifesting GI failure, which is immediately
life-threatening.
The WGAP of ESICM suggests using the proposed
deﬁnitions until the results of a broader consensus are
available. We encourage research to deﬁne explicit
characteristics of GI function in critically ill patients.
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